A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2016
At a glance
- Drugs VGX 1027 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors VGX Pharmaceuticals
- 01 Mar 2016 Results from this and the other phase I study, published in the Clinical Pharmacology in Drug Development.
- 08 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 27 Mar 2009 Status changed from active, no longer recruiting to completed, as reported in a medeia release from VGX Pharmaceuticals.